CA2083271A1 - Fibrin binding domain polypeptides and uses and methods of producing same - Google Patents
Fibrin binding domain polypeptides and uses and methods of producing sameInfo
- Publication number
- CA2083271A1 CA2083271A1 CA002083271A CA2083271A CA2083271A1 CA 2083271 A1 CA2083271 A1 CA 2083271A1 CA 002083271 A CA002083271 A CA 002083271A CA 2083271 A CA2083271 A CA 2083271A CA 2083271 A1 CA2083271 A1 CA 2083271A1
- Authority
- CA
- Canada
- Prior art keywords
- fibrin
- methods
- binding domain
- polypeptides
- binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000009123 Fibrin Human genes 0.000 title abstract 8
- 108010073385 Fibrin Proteins 0.000 title abstract 8
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 title abstract 8
- 229950003499 fibrin Drugs 0.000 title abstract 8
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 8
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 8
- 229920001184 polypeptide Polymers 0.000 title abstract 6
- 238000000034 method Methods 0.000 title abstract 5
- 101001027128 Homo sapiens Fibronectin Proteins 0.000 abstract 3
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 3
- 239000012216 imaging agent Substances 0.000 abstract 2
- 239000013612 plasmid Substances 0.000 abstract 2
- 239000000126 substance Substances 0.000 abstract 2
- 208000037260 Atherosclerotic Plaque Diseases 0.000 abstract 1
- 208000007536 Thrombosis Diseases 0.000 abstract 1
- 238000003384 imaging method Methods 0.000 abstract 1
- 239000003550 marker Substances 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/082—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being a RGD-containing peptide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/0043—Catheters; Hollow probes characterised by structural features
- A61M25/0045—Catheters; Hollow probes characterised by structural features multi-layered, e.g. coated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
- C07K1/1133—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by redox-reactions involving cystein/cystin side chains
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
- C07K14/3153—Streptokinase
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
Abstract
This invention provides an imaging agent which comprises a polypeptide labeled with an imageable marker, such polypep-tide having an amino acid sequence substantially present in the fibrin binding domain of naturally-occuring human fibronectin and being capable of binding to fibrin. The invention further provides a method wherein the imaging agent is used for imaging a fibrin-containing substance, i.e., a thrombus or atherosclerotic plaque.
Further provided are plasmids for expression of polypep-tides having an amino acid sequence substantially present in the fibrin binding domain of naturally-occuring human fibronectin and being capable of binding to fibrin, hosts containing these plasmids, methods of producing the polypeptides, methods of treat-ment using the polypeptides, and methods of recovering, refolding and reoxidizing the polypeptides. The invention also provides for purified polypeptides substantially free of other substances of human origin which have an amino acid sequence substantially present in the fibrin binding domain of naturally-occuring human fibronectin and which are capable of binding to fibrin.
Further provided are plasmids for expression of polypep-tides having an amino acid sequence substantially present in the fibrin binding domain of naturally-occuring human fibronectin and being capable of binding to fibrin, hosts containing these plasmids, methods of producing the polypeptides, methods of treat-ment using the polypeptides, and methods of recovering, refolding and reoxidizing the polypeptides. The invention also provides for purified polypeptides substantially free of other substances of human origin which have an amino acid sequence substantially present in the fibrin binding domain of naturally-occuring human fibronectin and which are capable of binding to fibrin.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US526,397 | 1990-05-21 | ||
US07/526,397 US5270030A (en) | 1988-12-29 | 1990-05-21 | Fibrin binding domain polypeptide and method of producing |
PCT/US1991/003584 WO1991017765A1 (en) | 1990-05-21 | 1991-05-21 | Fibrin binding domain polypeptides and uses and methods of producing same |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2083271A1 true CA2083271A1 (en) | 1991-11-22 |
CA2083271C CA2083271C (en) | 2002-04-09 |
Family
ID=24097174
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002083271A Expired - Lifetime CA2083271C (en) | 1990-05-21 | 1991-05-21 | Fibrin binding domain polypeptides and uses and methods of producing same |
Country Status (18)
Country | Link |
---|---|
US (4) | US5270030A (en) |
EP (1) | EP0651799B1 (en) |
JP (1) | JP3419772B2 (en) |
AT (1) | ATE183545T1 (en) |
AU (1) | AU660618B2 (en) |
CA (1) | CA2083271C (en) |
DE (1) | DE69131539T2 (en) |
DK (1) | DK0651799T3 (en) |
ES (1) | ES2137928T3 (en) |
FI (1) | FI108298B (en) |
GR (1) | GR3031708T3 (en) |
HK (1) | HK1013255A1 (en) |
HU (1) | HU216302B (en) |
IL (1) | IL98197A0 (en) |
NO (1) | NO310559B1 (en) |
NZ (1) | NZ238208A (en) |
RU (1) | RU2109750C1 (en) |
WO (1) | WO1991017765A1 (en) |
Families Citing this family (94)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5972890A (en) * | 1988-05-02 | 1999-10-26 | New England Deaconess Hospital Corporation | Synthetic peptides for arterial imaging |
US5679320A (en) * | 1988-12-29 | 1997-10-21 | Bio-Technology General Corp. | Fibrin binding domain polypeptides and uses and methods of producing same |
US7087722B1 (en) * | 1988-12-29 | 2006-08-08 | Savient Pharmaceuticals, Inc. | Fibrin binding domain polypeptides and uses and methods of producing same |
US5270030A (en) * | 1988-12-29 | 1993-12-14 | Bio-Technology General Corp. | Fibrin binding domain polypeptide and method of producing |
US6034233A (en) * | 1990-05-04 | 2000-03-07 | Isis Pharmaceuticals Inc. | 2'-O-alkylated oligoribonucleotides and phosphorothioate analogs complementary to portions of the HIV genome |
US5792742A (en) * | 1991-06-14 | 1998-08-11 | New York University | Fibrin-binding peptide fragments of fibronectin |
CA2110283A1 (en) * | 1992-03-31 | 1993-10-14 | Tatsutoshi Nakahata | Physiologically active protein and hemotopoietic stem cell growth agent |
US5968476A (en) * | 1992-05-21 | 1999-10-19 | Diatide, Inc. | Technetium-99m labeled peptides for thrombus imaging |
DK145092D0 (en) * | 1992-12-03 | 1992-12-03 | Novo Nordisk As | |
US5750088A (en) | 1993-03-30 | 1998-05-12 | The Dupont Merck Pharmaceutical Company | Stable hydrazones linked to a peptide moiety as reagents for the preparation of radiopharmaceuticals |
US5879657A (en) * | 1993-03-30 | 1999-03-09 | The Dupont Merck Pharmaceutical Company | Radiolabeled platelet GPIIb/IIIa receptor antagonists as imaging agents for the diagnosis of thromboembolic disorders |
US6218529B1 (en) * | 1995-07-31 | 2001-04-17 | Urocor, Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer |
WO1997043314A2 (en) * | 1996-05-16 | 1997-11-20 | The Texas A & M University System | Collagen binding protein compositions and methods of use |
US20030176663A1 (en) * | 1998-05-11 | 2003-09-18 | Eidgenossische Technische Hochscule | Specific binding molecules for scintigraphy |
KR100660509B1 (en) * | 1998-05-15 | 2006-12-22 | 지이 헬쓰케어 리미티드 | Labelled Glutamine and Lysine Analogues |
IN190822B (en) | 1998-12-24 | 2003-08-23 | Council Scient Ind Res | |
US6808698B1 (en) | 1999-03-26 | 2004-10-26 | Bristol-Myers Squibb Pharma Company | Method for localization of blood clots |
US6426145B1 (en) | 1999-05-20 | 2002-07-30 | Scimed Life Systems, Inc. | Radiopaque compositions for visualization of medical devices |
US6254852B1 (en) | 1999-07-16 | 2001-07-03 | Dupont Pharmaceuticals Company | Porous inorganic targeted ultrasound contrast agents |
US6685914B1 (en) * | 1999-09-13 | 2004-02-03 | Bristol-Myers Squibb Pharma Company | Macrocyclic chelants for metallopharmaceuticals |
WO2001062800A1 (en) * | 2000-02-24 | 2001-08-30 | Eidgenössische Technische Hochschule Zürich | Antibody specific for the ed-b domain of fibronectin, conjugates comprising said antibody, and their use for the detection and treatment of angiogenesis |
PL364358A1 (en) * | 2000-09-07 | 2004-12-13 | Schering Ag | Receptor in the edb fibronectin domain (ii) |
WO2002028267A2 (en) * | 2000-10-03 | 2002-04-11 | The Board Of Trustees Of The University Of Arkansas | Method for detecting and excising nonpalpable lesions |
US7226739B2 (en) | 2001-03-02 | 2007-06-05 | Isis Pharmaceuticals, Inc | Methods for rapid detection and identification of bioagents in epidemiological and forensic investigations |
US20040121314A1 (en) * | 2002-12-06 | 2004-06-24 | Ecker David J. | Methods for rapid detection and identification of bioagents in containers |
US20030027135A1 (en) | 2001-03-02 | 2003-02-06 | Ecker David J. | Method for rapid detection and identification of bioagents |
US20040121309A1 (en) | 2002-12-06 | 2004-06-24 | Ecker David J. | Methods for rapid detection and identification of bioagents in blood, bodily fluids, and bodily tissues |
US7666588B2 (en) | 2001-03-02 | 2010-02-23 | Ibis Biosciences, Inc. | Methods for rapid forensic analysis of mitochondrial DNA and characterization of mitochondrial DNA heteroplasmy |
US20020169288A1 (en) * | 2001-03-15 | 2002-11-14 | Magnus Hook | Collagen-binding adhesin from staphylococcus epidermidis and method of use |
US7217510B2 (en) | 2001-06-26 | 2007-05-15 | Isis Pharmaceuticals, Inc. | Methods for providing bacterial bioagent characterizing information |
US8073627B2 (en) | 2001-06-26 | 2011-12-06 | Ibis Biosciences, Inc. | System for indentification of pathogens |
US20030224476A1 (en) * | 2002-03-01 | 2003-12-04 | Szu-Yi Chou | Method of producing transglutaminase reactive compound |
CA2508726A1 (en) | 2002-12-06 | 2004-07-22 | Isis Pharmaceuticals, Inc. | Methods for rapid identification of pathogens in humans and animals |
US8046171B2 (en) | 2003-04-18 | 2011-10-25 | Ibis Biosciences, Inc. | Methods and apparatus for genetic evaluation |
US8057993B2 (en) | 2003-04-26 | 2011-11-15 | Ibis Biosciences, Inc. | Methods for identification of coronaviruses |
US8158354B2 (en) | 2003-05-13 | 2012-04-17 | Ibis Biosciences, Inc. | Methods for rapid purification of nucleic acids for subsequent analysis by mass spectrometry by solution capture |
US7964343B2 (en) | 2003-05-13 | 2011-06-21 | Ibis Biosciences, Inc. | Method for rapid purification of nucleic acids for subsequent analysis by mass spectrometry by solution capture |
US7319149B2 (en) * | 2003-06-13 | 2008-01-15 | Bristol-Myers Squibb Pharma Company | Chelants and macrocyclic metal complex radiopharmaceuticals thereof |
US7317104B2 (en) | 2003-06-13 | 2008-01-08 | Bristol-Myers Squibb Pharma Company | Chelants and macrocyclic metal complex radiopharmaceuticals thereof |
US8546082B2 (en) | 2003-09-11 | 2013-10-01 | Ibis Biosciences, Inc. | Methods for identification of sepsis-causing bacteria |
US8097416B2 (en) | 2003-09-11 | 2012-01-17 | Ibis Biosciences, Inc. | Methods for identification of sepsis-causing bacteria |
US7956175B2 (en) | 2003-09-11 | 2011-06-07 | Ibis Biosciences, Inc. | Compositions for use in identification of bacteria |
EP1758998B1 (en) | 2004-01-30 | 2010-12-15 | Quark Pharmaceuticals, Inc. | Oligoribonucleotides and methods of use thereof for treatment of fibrotic conditions and other diseases |
US7666592B2 (en) | 2004-02-18 | 2010-02-23 | Ibis Biosciences, Inc. | Methods for concurrent identification and quantification of an unknown bioagent |
US8119336B2 (en) | 2004-03-03 | 2012-02-21 | Ibis Biosciences, Inc. | Compositions for use in identification of alphaviruses |
WO2005117270A2 (en) | 2004-05-24 | 2005-12-08 | Isis Pharmaceuticals, Inc. | Mass spectrometry with selective ion filtration by digital thresholding |
US20050266411A1 (en) | 2004-05-25 | 2005-12-01 | Hofstadler Steven A | Methods for rapid forensic analysis of mitochondrial DNA |
US7811753B2 (en) | 2004-07-14 | 2010-10-12 | Ibis Biosciences, Inc. | Methods for repairing degraded DNA |
JP4468989B2 (en) | 2004-08-16 | 2010-05-26 | クアーク・ファーマスーティカルス、インコーポレイテッド | Use of RTP801 inhibitors for therapy |
WO2006135400A2 (en) | 2004-08-24 | 2006-12-21 | Isis Pharmaceuticals, Inc. | Methods for rapid identification of recombinant organisms |
NZ553987A (en) | 2004-09-28 | 2011-01-28 | Quark Pharmaceuticals Inc | Oligoribonucleotides and methods of use thereof for treatment of alopecia, acute renal failure and other diseases |
WO2006094238A2 (en) | 2005-03-03 | 2006-09-08 | Isis Pharmaceuticals, Inc. | Compositions for use in identification of adventitious viruses |
US8084207B2 (en) | 2005-03-03 | 2011-12-27 | Ibis Bioscience, Inc. | Compositions for use in identification of papillomavirus |
JP5162447B2 (en) * | 2005-04-13 | 2013-03-13 | アイビス バイオサイエンシズ インコーポレイティッド | Composition for use in adenovirus identification |
US7414254B2 (en) * | 2005-06-28 | 2008-08-19 | United Pharmacy Partners, Inc. | Tungsten pig for radio-pharmaceuticals |
CA2616281C (en) | 2005-07-21 | 2014-04-22 | Isis Pharmaceuticals, Inc. | Methods for rapid identification and quantitation of mitochondrial dna variants |
NL2000439C2 (en) | 2006-01-20 | 2009-03-16 | Quark Biotech | Therapeutic applications of inhibitors of RTP801. |
AU2007353877B2 (en) | 2006-09-14 | 2012-07-19 | Ibis Biosciences, Inc. | Targeted whole genome amplification method for identification of pathogens |
JP2010507387A (en) | 2006-10-25 | 2010-03-11 | クアーク・ファーマスーティカルス、インコーポレイテッド | Novel siRNA and method of using the same |
WO2008104002A2 (en) | 2007-02-23 | 2008-08-28 | Ibis Biosciences, Inc. | Methods for rapid forensic dna analysis |
US9598724B2 (en) | 2007-06-01 | 2017-03-21 | Ibis Biosciences, Inc. | Methods and compositions for multiple displacement amplification of nucleic acids |
JP5646997B2 (en) | 2007-10-03 | 2014-12-24 | クォーク ファーマシューティカルズ インコーポレーティッドQuark Pharmaceuticals,Inc. | Novel siRNA structure |
US8253725B2 (en) * | 2007-12-28 | 2012-08-28 | St. Jude Medical, Atrial Fibrillation Division, Inc. | Method and system for generating surface models of geometric structures |
WO2009147684A2 (en) | 2008-06-06 | 2009-12-10 | Quark Pharmaceuticals, Inc. | Compositions and methods for treatment of ear disorders |
US8148163B2 (en) | 2008-09-16 | 2012-04-03 | Ibis Biosciences, Inc. | Sample processing units, systems, and related methods |
US8534447B2 (en) | 2008-09-16 | 2013-09-17 | Ibis Biosciences, Inc. | Microplate handling systems and related computer program products and methods |
WO2010033599A2 (en) | 2008-09-16 | 2010-03-25 | Ibis Biosciences, Inc. | Mixing cartridges, mixing stations, and related kits, systems, and methods |
US8864821B2 (en) | 2008-11-26 | 2014-10-21 | Visen Medical, Inc. | Methods and compositions for identifying subjects at risk of developing stent thrombosis |
WO2010080452A2 (en) | 2008-12-18 | 2010-07-15 | Quark Pharmaceuticals, Inc. | siRNA COMPOUNDS AND METHODS OF USE THEREOF |
EP2396803A4 (en) | 2009-02-12 | 2016-10-26 | Ibis Biosciences Inc | Ionization probe assemblies |
GB0905328D0 (en) * | 2009-03-27 | 2009-05-13 | Ge Healthcare Ltd | Indole derivatives |
US8950604B2 (en) | 2009-07-17 | 2015-02-10 | Ibis Biosciences, Inc. | Lift and mount apparatus |
EP2454000A4 (en) | 2009-07-17 | 2016-08-10 | Ibis Biosciences Inc | Systems for bioagent identification |
EP2957641B1 (en) | 2009-10-15 | 2017-05-17 | Ibis Biosciences, Inc. | Multiple displacement amplification |
CA2776568A1 (en) | 2009-11-26 | 2011-06-03 | Quark Pharmaceuticals, Inc. | Sirna compounds comprising terminal substitutions |
US8778904B2 (en) | 2009-12-09 | 2014-07-15 | Quark Pharmaceuticals, Inc. | Methods and compositions for treating diseases, disorders or injury of the CNS |
WO2011084193A1 (en) | 2010-01-07 | 2011-07-14 | Quark Pharmaceuticals, Inc. | Oligonucleotide compounds comprising non-nucleotide overhangs |
CA2801928C (en) | 2010-06-24 | 2018-04-10 | Quark Pharmaceuticals, Inc. | Double stranded rna compounds to rhoa and use thereof |
CA2818024C (en) | 2010-12-06 | 2019-09-24 | Quark Pharmaceuticals, Inc. | Double stranded oligonucleotide compounds comprising positional modifications |
US9796979B2 (en) | 2011-03-03 | 2017-10-24 | Quark Pharmaceuticals Inc. | Oligonucleotide modulators of the toll-like receptor pathway |
CN103562387A (en) | 2011-03-03 | 2014-02-05 | 夸克医药公司 | Oligonucleotide modulators of the toll-like receptor pathway |
CN103917647B (en) | 2011-11-03 | 2020-07-10 | 夸克制药公司 | Methods and compositions for neuroprotection |
WO2013070821A1 (en) | 2011-11-08 | 2013-05-16 | Quark Pharmaceuticals, Inc. | Methods and compositions for treating diseases, disorders or injury of the nervous system |
CA2858630A1 (en) | 2012-01-12 | 2013-07-18 | Quark Pharmaceuticals, Inc. | Combination therapy for treating hearing and balance disorders |
US9611473B2 (en) | 2012-09-12 | 2017-04-04 | Quark Pharmaceuticals, Inc. | Double-stranded nucleic acid compounds |
DK2895608T3 (en) | 2012-09-12 | 2019-01-21 | Quark Pharmaceuticals Inc | DOUBLE-STRENGTHED OIGONUCLEOTIDE MOLECULES FOR P53 AND PROCEDURES FOR USING IT |
BR112015004747A2 (en) | 2012-09-12 | 2017-11-21 | Quark Pharmaceuticals Inc | p53 double stranded oligonucleotide molecules and methods of using them |
WO2015015498A1 (en) | 2013-07-31 | 2015-02-05 | Qbi Enterprises Ltd. | Methods of use of sphingolipid polyalkylamine oligonucleotide compounds |
EP3027222A1 (en) | 2013-07-31 | 2016-06-08 | QBI Enterprises Ltd. | Sphingolipid-polyalkylamine-oligonucleotide compounds |
US9459201B2 (en) | 2014-09-29 | 2016-10-04 | Zyomed Corp. | Systems and methods for noninvasive blood glucose and other analyte detection and measurement using collision computing |
US9554738B1 (en) | 2016-03-30 | 2017-01-31 | Zyomed Corp. | Spectroscopic tomography systems and methods for noninvasive detection and measurement of analytes using collision computing |
EP3671511B1 (en) | 2018-12-19 | 2022-07-06 | Rohde & Schwarz GmbH & Co. KG | Communication system and method |
EP3922720A1 (en) | 2020-06-09 | 2021-12-15 | Universidad de Murcia | Therapy to prevent adverse cardiac remodeling following an acute myocardial infarction |
ES2894201B2 (en) * | 2020-08-05 | 2022-09-29 | Fundacion Para La Investig Biomedica Del Hospital Gregorio Maranon | RADIOACTIVE COMPOUNDS BASED ON SELECTIVE BACTERIA PROTEINS FOR THE NON-INVASIVE DETECTION OF INFECTIOUS FOCUSES |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4315906A (en) * | 1979-05-21 | 1982-02-16 | New England Nuclear Corporation | Cold insoluble globulin, its purification and use |
US4455290A (en) * | 1981-04-02 | 1984-06-19 | Research Corporation | Inhibition of fibrin polymerization by a peptide isolated from fibrin Fragment D1 |
US4663146A (en) * | 1983-07-29 | 1987-05-05 | Codon Genetic Engineering Laboratories | Methods and compositions for the diagnosis of bloodclots using plasminogen activator |
US4587122A (en) * | 1985-04-23 | 1986-05-06 | The Green Cross Corporation | Fibronectin-dextran-drug complex and method of preparation thereof |
GB8516421D0 (en) * | 1985-06-28 | 1985-07-31 | Biotechnology Interface Ltd | Fibronectins |
US4734362A (en) * | 1986-02-03 | 1988-03-29 | Cambridge Bioscience Corporation | Process for purifying recombinant proteins, and products thereof |
AU2258788A (en) * | 1987-07-07 | 1989-01-30 | Cytrx Biopool Ltd. | Fibrin-binding compound and method |
US4839464A (en) * | 1987-08-25 | 1989-06-13 | Regents Of The University Of Minnesota | Polypeptides with fibronectin activity |
JP2561122B2 (en) * | 1988-04-13 | 1996-12-04 | 寳酒造株式会社 | Functional polypeptide |
JP2561131B2 (en) * | 1988-06-30 | 1996-12-04 | 寳酒造株式会社 | Cell adhesion activity polypeptide |
US5270030A (en) * | 1988-12-29 | 1993-12-14 | Bio-Technology General Corp. | Fibrin binding domain polypeptide and method of producing |
IL92925A0 (en) * | 1988-12-29 | 1990-09-17 | Bio Technology General Corp | Cloning and production of human fibronectin polypeptide analogs and method of using such polypeptide analogs |
US5026537A (en) * | 1989-04-06 | 1991-06-25 | Centocor, Inc. | Methods for imaging atherosclerotic plaque |
-
1990
- 1990-05-21 US US07/526,397 patent/US5270030A/en not_active Expired - Lifetime
-
1991
- 1991-05-21 DK DK91911888T patent/DK0651799T3/en active
- 1991-05-21 AU AU80760/91A patent/AU660618B2/en not_active Expired
- 1991-05-21 NZ NZ238208A patent/NZ238208A/en not_active IP Right Cessation
- 1991-05-21 DE DE69131539T patent/DE69131539T2/en not_active Expired - Lifetime
- 1991-05-21 EP EP91911888A patent/EP0651799B1/en not_active Expired - Lifetime
- 1991-05-21 CA CA002083271A patent/CA2083271C/en not_active Expired - Lifetime
- 1991-05-21 JP JP51119791A patent/JP3419772B2/en not_active Expired - Lifetime
- 1991-05-21 WO PCT/US1991/003584 patent/WO1991017765A1/en active IP Right Grant
- 1991-05-21 RU RU92016360/13A patent/RU2109750C1/en active
- 1991-05-21 ES ES91911888T patent/ES2137928T3/en not_active Expired - Lifetime
- 1991-05-21 HU HU9203516A patent/HU216302B/en unknown
- 1991-05-21 IL IL98197A patent/IL98197A0/en unknown
- 1991-05-21 AT AT91911888T patent/ATE183545T1/en not_active IP Right Cessation
-
1992
- 1992-11-13 NO NO19924405A patent/NO310559B1/en not_active IP Right Cessation
- 1992-11-20 FI FI925296A patent/FI108298B/en active
-
1993
- 1993-05-04 US US08/058,241 patent/US5455158A/en not_active Expired - Lifetime
-
1995
- 1995-03-24 US US08/409,750 patent/US5965383A/en not_active Expired - Lifetime
-
1997
- 1997-08-11 US US08/909,140 patent/US6121426A/en not_active Expired - Fee Related
-
1998
- 1998-12-22 HK HK98114600A patent/HK1013255A1/en not_active IP Right Cessation
-
1999
- 1999-11-03 GR GR990402800T patent/GR3031708T3/en unknown
Also Published As
Publication number | Publication date |
---|---|
FI108298B (en) | 2001-12-31 |
EP0651799A1 (en) | 1995-05-10 |
NO310559B1 (en) | 2001-07-23 |
DE69131539D1 (en) | 1999-09-23 |
US5455158A (en) | 1995-10-03 |
JPH05508766A (en) | 1993-12-09 |
ATE183545T1 (en) | 1999-09-15 |
US6121426A (en) | 2000-09-19 |
AU8076091A (en) | 1991-12-10 |
GR3031708T3 (en) | 2000-02-29 |
NO924405L (en) | 1993-01-13 |
US5270030A (en) | 1993-12-14 |
HU216302B (en) | 1999-06-28 |
DE69131539T2 (en) | 2000-05-04 |
FI925296A0 (en) | 1992-11-20 |
NO924405D0 (en) | 1992-11-13 |
FI925296A (en) | 1992-11-20 |
JP3419772B2 (en) | 2003-06-23 |
CA2083271C (en) | 2002-04-09 |
IL98197A0 (en) | 1992-06-21 |
EP0651799B1 (en) | 1999-08-18 |
HUT66189A (en) | 1994-10-28 |
EP0651799A4 (en) | 1993-10-05 |
US5965383A (en) | 1999-10-12 |
NZ238208A (en) | 1993-01-27 |
HK1013255A1 (en) | 1999-08-20 |
AU660618B2 (en) | 1995-07-06 |
RU2109750C1 (en) | 1998-04-27 |
DK0651799T3 (en) | 2000-03-06 |
WO1991017765A1 (en) | 1991-11-28 |
HU9203516D0 (en) | 1993-04-28 |
ES2137928T3 (en) | 2000-01-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2083271A1 (en) | Fibrin binding domain polypeptides and uses and methods of producing same | |
RU92016360A (en) | VISUALIZING AGENT, COMPOSITION, METHOD OF DETECTING MATERIAL, PLASMIDES, CELL, METHODS OF OBTAINING POLYPEPTIDE, POLYPEPTIDE, METHOD OF RECOVERY POLYPEPTIDE CONFORMATION | |
CA2168429A1 (en) | Expression of fusion polypeptides transported out of cytoplasm without leader sequences | |
GB2246783A (en) | Fusion proteins containing n-terminal fragments of human serum albumin | |
AU3530589A (en) | Osteogenic devices | |
DK601786A (en) | HIS UNKNOWN PROCOAGULATION PROTEINS | |
AU2058888A (en) | Variants of bovine pancreatic trypsin inhibitor produced by recombinant DNA technology, process, expression vector and recombinant host therefor and pharmaceutical use thereof | |
DE68929045D1 (en) | METHOD FOR PRODUCING AND SELECTING PEPTIDES WITH SPECIFIC PROPERTIES | |
DE59401383D1 (en) | Process for the preparation of amino substituted thioethers | |
HU9501288D0 (en) | Recombinant method and host for manufacture of xylitol | |
CA2111645A1 (en) | Fibrinogen fragment e peptides and antibodies thereto | |
DK610888A (en) | CARDIODILATE INGREDIENT, METHOD OF PREPARING THEREOF AND ITS USE | |
FR2546164B1 (en) | NOVEL PEPTIDE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION AS ELASTASE INHIBITORS | |
DE3873273D1 (en) | METHOD FOR SELECTIVE CLEAVAGE OF FUSION PROTEINS. | |
EP0317279A3 (en) | Peptides for use in the purification of factor viii | |
DE59004279D1 (en) | Process for the C-terminal modification of proteins. | |
CA2329144A1 (en) | New peptide fragments for protein purification | |
DK627389A (en) | PROTEINS AND DERIVATIVES THEREOF | |
WO2002059317A3 (en) | Cub domain protein zcub3 and materials and methods for making it |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKEX | Expiry |